[Somatostatin].
Somatostatin, under physiological conditions, is a regulator of thyroid stimulating hormone, growth hormone, pancreatic islet-cell hormones and gastrin. In pharmacological dosage, gastric acid output, splanchnic blood flow and plasma renin levels, are influenced. A possible therapeutic effect on increased growth hormone secretion, disturbances of carbohydrate metabolism, gastroenteropathies and renal hypertension, is discussed. The clinical application is limited by the short biological half-life of the substance and the unspecific action on several organs.
D000172:Acromegaly / Q000188:drug therapy; D000818:Animals; D003920:Diabetes Mellitus / Q000188:drug therapy; D003930:Diabetic Retinopathy / Q000188:drug therapy; D005750:Gastric Juice / Q000378:metabolism; D005755:Gastrins / Q000378:metabolism; D013006:Growth Hormone / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007515:Islets of Langerhans / Q000378:metabolism; D010195:Pancreatitis / Q000188:drug therapy; D012083:Renin / Q000097:blood; D013004:Somatostatin / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use; D013972:Thyrotropin / Q000378:metabolism; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy
D005755:Gastrins; D013004:Somatostatin; D013972:Thyrotropin; D013006:Growth Hormone; D012083:Renin
Somatostatin.